Slide 1 - Oncoletter

Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for Multiple Myeloma (MM): a randomized phase 3 study of the European Myeloma Network
(EMN02/HO95 MM trial)
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Background
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Background. 2
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 4
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 5
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 6
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 7
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 8
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 9
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 10
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 11
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 12
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 13
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 14
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 15
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 16
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 17
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 18
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 19
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Slide 20
Presented By Michele Cavo at 2016 ASCO Annual Meeting